Respiratory system involvement in antineutrophil cytoplasmic-associated systemic vasculitides: Clinical, pathological, radiological and therapeutic considerations

Drugs in R and D

Volumn 8, Issue 1, 2007, Pages 25-42

  Pesci, Alberto ^a   Manganelli, Paolo ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC RHINITIS; ANCA ASSOCIATED VASCULITIS; ANEMIA; ARTIFICIAL VENTILATION; ASTHMA; BLADDER CANCER; BRONCHOSCOPY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULONEPHRITIS; HEMOPTYSIS; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY DISEASE; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG HEMORRHAGE; LUNG KIDNEY SYNDROME; LUNG LAVAGE; MAINTENANCE THERAPY; META ANALYSIS; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; REVIEW; SUBGLOTTIC STENOSIS; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RESPIRATORY TRACT DISEASES; VASCULITIS;

EID: 33846704195     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708010-00003     Document Type: Review

References (143)

1. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med 1978; 89: 660-76
2. Gross WL. Immunopathogenesis of vasculitis. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby, 1998: 7.19.1-19.8.3
3. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-23
4. Manganelli P, Fietta P, Carotti M, et al. Respiratory system involvement in the systemic vasculitides. Clin Exp Rheum 2006; 24 Suppl. 41: S48-59
5. Pavone L, Grasselli C, Chierici E, et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 2006; 33: 1299-306
6. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98
7. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32
8. Stone JH. Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2003; 48: 2299-309
9. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39: 1754-60
10. Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151: 522-6
11. Belostotsky VM, Shah V, Dillon M. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17: 754-61
12. Rottem M, Fauci AS, Hallahan CW, et al. Wegener's granulomatosis in children and adolescent: clinical presentation and outcome. J Pediatr 1993; 122: 26-31
13. Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55: 502-10
14. Bosch X, López-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary haemorrhage. Arch Pathol Lab Med 1994; 118: 517-22
15. ter Maaten JC, Franssen CFM, Gans ROB, et al. Respiratory failure in ANCA-associated vasculitis. Chest 1996; 110: 357-62
16. Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage: update on diagnosis and management. Chest 1996; 110: 1305-16
17. Louthrenoo W, Norasetthada A, Khunamornpong S, et al. Childhood Churg-Strauss syndrome. J Rheumatol 1999; 26: 1387-93
18. Boyer D, Vargas SO, Slattery D, et al. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 2006; 118: 914-20
19. Lanham JC, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63: 65-81
20. Abril A, Calamia KT, Cohen MD. The Churg-Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 2003; 33: 106-14
21. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine 1999; 78: 26-37
22. Yamashita Y, Yorioka N, Taniguchi Y, et al. Nonasthmatic case of Churg-Strauss syndrome with rapidly progressive glomerulonephritis. Intern Med 1998; 37: 561-3
23. Malik TQ, Youmbissi TJ, Gacha R, et al. Atypical presentation of Churg-Strauss syndrome: another "forme fruste" of the disease? Am J Med Sci 2002; 324: 276-8
24. Sevinc A, Hasanouglu HC, Gokirmak M, et al. Allergic granulomatosis and angiitis in the absence of asthma and blood eosinophilia: a rare presentation of limited Churg-Strauss syndrome. Rheumatol Int 2004; 24: 301-4
25. Clutterbuck EJ, Pusey CD. Severe alveolar haemorrhage in Churg-Strauss syndrome. Eur J Respir Dis 1987; 71: 158-63
26. Lai R-S, Lin S-L, Lai N-S, et al. Churg-Strauss syndrome presenting with pulmonary capillaritis and diffuse alveolar hemorrhage. Scand J Rheumatol 1998; 27: 230-2
27. Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763-71
28. Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology 2002; 41: 1286-94
29. Erzurum SC, Underwood GA, Hamilos DL, et al. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95: 1357-9
30. Guillevin L, Durant-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30
31. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with myeloperoxidase-ANCA. Pediatr Nephrol 2006; 21: 46-53
32. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar haemorrhage: a study of 29 cases and review of the literature. Medicine 2000; 79: 222-33
33. Schwarz MI, Mortenson RL, Colby TV, et al. Pulmonary capillaritis: the association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993; 148: 507-11
34. Brugiere O, Raffy O, Sleiman C, et al. Progressive obstructive lung disease associated with microscopic polyangiitis. Am J Respir Crit Care Med 1997; 155: 739-42
35. Becker-Merok A, Nessent JC, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis. Scand J Rheumatol 1999; 28: 254-6
36. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003; 123: 297-301
37. Watz H, Hammerl P, Matter C, et al. Bronchioloalveolar carcinoma of the lung associated with a highly positive pANCA-titer and clinical signs of microscopic polyangiitis [in German]. Pneumologie 2004; 58: 493-8
38. Bosch X, Font J. The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Lupus 1999; 8: 258-62
39. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005; 38: 93-103
40. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-53
41. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35
42. Sablè-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg Strauss-syndrome. Ann Intern Med 2005; 143: 632-8
43. Russell KA, Wiegert E, Schroeder DR, et al. Detection of antineutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196-203
44. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 2003; 49: 151-5
45. Birck R, Schmitt WH, Kaelsch IA, et al. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23
46. Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41: 445-52
47. Gross WL. Churg-Strauss syndrome: update on recent development. Curr Opin Rheumatol 2002; 14: 11-4
48. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250-6
49. Rosenberg DM, Weinberger SE, Fulmer JD, et al. Functional correlates of lung involvement in Wegener's granulomatosis: use of pulmonary function tests in staging and follow-up. Am J Med 1980; 69: 387-94
50. Newall C, Schinke S, Savage CO, et al. Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology 2005; 44: 623-8
51. Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis: a clinical and imaging study of 77 cases. Chest 1990; 97: 906-12
52. Papiris SA, Manoussakis MN, Drosos AA, et al. Imaging of thoracic Wegener's granulomatosis: the computed tomographic appearance. Am J Med 1992; 93: 529-36
53. Seo JB, Im JG, Chung JW, et al. Pulmonary vasculitis: the spectrum of radiological findings. Br J Radiol 2000; 73: 1224-31
54. Rockall AG, Rickards D, Shaw PJ. Imaging of the pulmonary manifestations of systemic disease. Postgrad Med J 2001; 77: 621-38
55. Aberle DR, Gamsu G, Lynch D. Thoracic manifestations of Wegener's granulomatosis: diagnosis and course. Radiology 1990; 174: 703-9
56. Kuhlman JE, Hruban RH, Fishman EK. Wegener's granulomatosis: CT features of parenchymal lung disease. J Comput Assist Tomogr 1991; 15: 948-52
57. Lee SK, Kim TS, Fujimoto K, et al. Thoracic manifestations of Wegener's granulomatosis: CT findings in 30 patients. Eur Radiol 2003; 13: 43-51
58. Komócsi A, Reuter M, Heller M, et al. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high resolution computed tomography. Eur Radiol 2003; 13: 36-42
59. Primack SL, Hartman TE, Lee KS, et al. Pulmonary nodules and the CT halo sign. Radiology 1994; 190: 513-5
60. Haas C, Geneau C, Odinot JM, et al. Allergic angiitis and granulomatosis: Churg-Strauss syndrome. Retrospective study of 16 cases. Ann Med Interne 1991; 142: 335-42
61. Silva CI, Muller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging 2005; 20: 74-80
62. Collins CE, Quismorio FP. Pulmonary involvement in microscopic polyangiitis. Curr Opin Pulm Med 2005; 11: 447-51
63. Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 1997; 10: 2738-43
64. Hoffman GS, Sechler JMG, Gallin JI, et al. Bronchoalveolar lavage analysis in Wegener's granulomatosis: a method to study disease pathogenesis. Am Rev Respir Dis 1991; 143: 401-7
65. Schnabel A, Csernok E, Gross WL. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's granulomatosis. Am J Respir Crit Care Med 2000; 161: 399-40
66. Schnabel A, Reuter M, Gloeckner K, et al. Bronchoalveolar lavage cell profile in Wegener's granulomatosis. Respir Med 1999; 93: 498-506
67. Csernok E, Trabandt A, Muller A, et al. Cytokine profile in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42: 742-50
68. Olivieri D, Pesci A, Bertorelli G. Eosinophilic alveolitis in immunologic interstitial lung disorders. Lung 1990; 168 Suppl.: 964-73
69. Wallaert B, Gosset P, Prin L, et al. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur Respir J 1993; 6: 413-7
70. Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999; 54: 771-8
71. Manganelli P, Giacosa R, Fietta P, et al. Familial vasculitides: Churg-Strauss syndrome and Wegener's granulomatosis in two first-degree relatives. J Rheumatol 2003; 30: 618-21
72. Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis: review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 19: 315-33
73. Gaudin PB, Askin FB, Falk RJ, et al. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104: 7-16
74. Devankey KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14: 555-64
75. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung: a review. Am J Clin Pathol 2000; 114: 767-72
76. Bacciu A, Bacciu S, Mercante G, et al. Ear-nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126: 503-9
77. Rasmussen N, Abramowicz D, Andrassy K, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101 Suppl. 1: 29-34
78. Jayne DRW, Rasmussen N, for the European Community Systemic Vasculitis Clinical Trials Study Group (ECSYSVAS-TRIAL). Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trial Study Group. Mayo Clin Proc 1997; 72: 737-47
79. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985; 60: 27-32
80. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9
81. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13
82. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5
83. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134-9
84. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-40
85. Metzler C, Hellmich B, Gause A, et al. Churg-Strauss syndrome: successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22 Suppl. 36: S52-61
86. Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8
87. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-27
88. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37: 919-24
89. Lê Thu Huong D, Papo T, Piette JC, et al. Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis. Clin Exp Rheumatol 1996; 14: 9-16
90. Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-63
91. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45
92. Gaskin G, Pusey C. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5: 176-81
93. Frasca GM, Soverini ML, Falaschini A, et al. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther Apher Dial 2003; 7: 540-6
94. Jayne DRW, Esnault VLM, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207-19
95. Jayne DRW, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93: 433-9
96. Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13: 1953-60
97. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-7
98. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41: 1126-32
99. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF alpha blockade. Immunobiology 2002; 206: 496-501
100. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFα blockade in relapsing vasculitis [abstract]. Ann Rheum Dis 2002; 61: 559
101. Booth A, Harper L, Hammad T, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-21
102. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-54
103. The Wegener's Granulomatosis Etanercept Trial (WEGT) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61
104. + T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160: 3602-9
105. - T cells are a major source of interferon-γ and tumor necrosis factor-α in Wegener's granulomatosis. Am J Pathol 2002; 160: 1717-24
106. Mestre M, Bas J, Alsina J, et al. Depleting effects of antithymotis cyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 1999; 31: 2254-5
107. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-8
108. Voswinkel J, Mueller A, Kraemer JA, et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859-64
109. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40
110. Keogh K, Wylam M, Stone J, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8
111. Keogh K, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7
112. Arie PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8
113. Flossmann O, Jones RB, Jayne DRW, et al. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 2006; 65: 841-4
114. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20: 1083-92
115. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370-4
116. Simon HU, Seelbach H, Ehmann R, et al. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 2003; 58: 1250-5
117. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
118. Gordon M, Luqmani RA, Adu D, et al. Relapse in patients with systemic vasculitis. Q J Med 1993; 86: 779-89
119. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53
120. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 1307-11
121. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small vessel vasculitis. Am J Kidney Dis 2003; 42: 1149-53
122. Jayne D, Rasmussen N, Andrasy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
123. Slot MC, Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73
124. Reinhold-Keller E, Fink C, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32
125. Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-73
126. Langford CA, Talar-Williams C, Barron KS, et al. Use of cyclophosphamide-induction methotrexate-maintenance regi-men for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463-9
127. de Groot K, Rasmussen N, Bacon PA. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9
128. Chong AS, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140-5
129. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004; 63: 315-20
130. McMurray RW, Harisdangkul V. Mycophenolate mofetil: selecantitive T cell inhibition. Am J Med Sci 2002; 323: 194-6
131. Nowack R, Göbel U, Kloosker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-71
132. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57: 421-4
133. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-83
134. Joy MS, Hogan SI, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-32
135. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994; 20: 12-7
136. Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996; 89: 15-23
137. Stegeman CA, Cohen Tervaert JW, de Jong PE, et al. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996; 335: 16-20
138. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006; 3: 48-57
139. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-71
140. Kyndt X, Reumaux D, Bridoux F, et al. Serial measurement of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 527-33
141. Girard T, Mahr A, Noel L-H, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology 2001; 40: 147-51
142. Luqmani RA, Flossmann O. Outcome in small-vessel systemic vasculitis. J Rheumatol 2006; 33: 1224-7
143. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine 1996; 75: 17-28